Effets indésirables des nouvelles thérapies du cancer du sein : quand faut-il réagir ? [Adverse effects of new breast cancer therapies : when to react ?]
Fiche du document
18 mai 2022
- doi: 10.53738/REVMED.2022.18.782.997
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.782.997
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35583279
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6573A443A7769
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
BreastsCiter ce document
N. Dris et al., « Effets indésirables des nouvelles thérapies du cancer du sein : quand faut-il réagir ? [Adverse effects of new breast cancer therapies : when to react ?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.782.997
Métriques
Partage / Export
Résumé
In last years, the therapeutic arsenal against breast cancer increased considerably with the arrival of signaling pathway inhibitors, immunotherapy, PARP inhibitors, tyrosine kinase inhibitors and antibody-drug conjugates. Consequently, the range of potential adverse events has also widened and differs from the usual chemotherapies and endocrine therapies. Depending on the administered therapy, the same symptoms can be harmless and treated symptomatically or the warning sign of a potential serious complication requiring a rapid action. We therefore discuss in this article the therapeutic role and some typical adverse events of these new therapies.